Mediaboss Marketing

PRESS RELEASE: MOLOGEN AG: Successful capital increase enables phase III study with immunotherapy MGN 1703 (colon cancer)

DGAP-News: MOLOGEN AG / Key word(s): Capital Increase MOLOGEN AG: Successful capital increase enables phase III study with immunotherapy MGN 1703 (colon cancer)

06.02.2014 / 17:27

=--------------------------------------------------------------------

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA.

PRESS RELEASE N 02 / 2014 of 02/06/2014

MOLOGEN AG: Successful capital increase enables phase III study with immunotherapy MGN 1703 (colon cancer)

Berlin, February 6, 2014 - MOLOGEN AG has successfully concluded the capital increase, which was resolved yesterday. The issue price was set at EUR 10.20 per new share. In the context of a private placement the capital increase was fully placed with qualified investors in the amount of 1,541,244 shares (equivalent to 10 per cent of the current share capital). The share capital will therefore be increased by issuing 1,541,244 new no-par value bearer shares from currently 15,419,512 Euros to then 16,960,756 Euros. The gross proceeds amount to approximately 15.7 million Euros.

The proceeds from the capital increase will be used to further strengthen the equity base as well as to finance the development of the product pipeline and the proceeds enable in particular to start the planned pivotal clinical phase III study with MGN1703 in metastatic colorectal cancer.

Dr. Matthias Schroff, CEO of MOLOGEN AG: 'The planning for the pivotal study has been largely completed. Thus, our cancer immunotherapy MGN1703 can enter into the final clinical phase this year in order to confirm the previous excellent results in a significantly larger number of patients. We are delighted about the trust of the investors.'

Read more:
PRESS RELEASE: MOLOGEN AG: Successful capital increase enables phase III study with immunotherapy MGN 1703 (colon ...